Boston Scientific (NYSE:BSX) Sets New 52-Week Low - Here's Why

Key Points

• Boston Scientific hit a new 52‑week low of $55.94, trading below its 50‑day ($67.06) and 200‑day ($84.57) moving averages on heavy volume (~5.15M shares), indicating recent selling pressure.
• A series of analyst cuts (e.g., Daiwa to "hold", Stifel, RBC and Baird trimming targets) lowered near‑term sentiment, but MarketBeat's consensus remains a Moderate Buy with an average price target of $93.91.
• The company posted a modest quarterly beat—EPS $0.80 vs. $0.79 and revenue $5.20B vs. $5.19B (revenue +11.6% YoY)—and issued Q2 2026 guidance of $0.820–0.840 EPS and FY 2026 guidance of $3.340–3.410 EPS.

Boston Scientific Corporation (NYSE:BSX - Get Free Report) hit a new 52-week low on Tuesday . The company traded as low as $55.94 and last traded at $55.9820, with a volume of 5151806 shares trading hands. The stock had previously closed at $56.85.

Analysts Set New Price Targets

A number of research firms recently issued reports on BSX. Daiwa Securities Group lowered Boston Scientific from a "strong-buy" rating to a "hold" rating in a report on Wednesday, April 29th. Stifel Nicolaus cut their target price on Boston Scientific from $90.00 to $85.00 and set a "buy" rating on the stock in a research report on Tuesday, April 21st. Royal Bank Of Canada cut their target price on Boston Scientific from $105.00 to $100.00 and set an "outperform" rating on the stock in a research report on Thursday, April 23rd. Robert W. Baird cut their target price on Boston Scientific from $86.00 to $78.00 and set an "outperform" rating on the stock in a research report on Thursday, April 23rd. Finally, Truist Financial dropped their price target on Boston Scientific from $90.00 to $85.00 and set a "buy" rating on the stock in a research report on Thursday, April 23rd. One analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $93.91.

Boston Scientific Price Performance

The company has a quick ratio of 1.08, a current ratio of 1.62 and a debt-to-equity ratio of 0.46. The stock has a market cap of $83.20 billion, a P/E ratio of 23.42, a price-to-earnings-growth ratio of 1.04 and a beta of 0.62. The business's 50-day simple moving average is $67.06 and its two-hundred day simple moving average is $84.57.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, beating analysts' consensus estimates of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.68%. The company had revenue of $5.20 billion during the quarter, compared to analyst estimates of $5.19 billion. During the same period last year, the business earned $0.75 earnings per share. Boston Scientific's revenue was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Sell-side analysts expect that Boston Scientific Corporation will post 3.38 EPS for the current year.

Hedge Funds Weigh In On Boston Scientific

Large investors have recently modified their holdings of the company. Crown Wealth Group LLC raised its stake in Boston Scientific by 4.7% in the third quarter. Crown Wealth Group LLC now owns 2,238 shares of the medical equipment provider's stock valued at $218,000 after purchasing an additional 100 shares in the last quarter. Claret Asset Management Corp raised its stake in Boston Scientific by 4.4% in the third quarter. Claret Asset Management Corp now owns 2,400 shares of the medical equipment provider's stock valued at $234,000 after purchasing an additional 102 shares in the last quarter. Cary Street Partners Investment Advisory LLC raised its stake in Boston Scientific by 5.1% in the third quarter. Cary Street Partners Investment Advisory LLC now owns 2,106 shares of the medical equipment provider's stock valued at $206,000 after purchasing an additional 103 shares in the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors raised its stake in Boston Scientific by 2.3% in the third quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors now owns 4,776 shares of the medical equipment provider's stock valued at $466,000 after purchasing an additional 108 shares in the last quarter. Finally, Kera Capital Partners Inc. raised its stake in Boston Scientific by 3.3% in the third quarter. Kera Capital Partners Inc. now owns 3,407 shares of the medical equipment provider's stock valued at $333,000 after purchasing an additional 109 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors.

Boston Scientific Company Profile

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.